Approval · Notice of Compliance 34329 · 2024
BIJUVA: Notice of Compliance 34329
Issued November 1, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34329
- Date
- November 1, 2024
- Company
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information. Update to Patient Medication Information. Update to package insert
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BIJUVA | Not yet assigned | — |
Medicinal ingredients
- PROGESTERONE 100 MG per CAP
- ESTRADIOL HEMIHYDRATE 0.5 MG per CAP
- ESTRADIOL HEMIHYDRATE 1 MG per CAP